Physician profile
Barry Gach
NPI 1699700070
$6,466.64
in general payments reported to CMS, 2019-2025
26 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $781 · 2021: $899 · 2022: $1,163 · 2023: $445 · 2024: $725 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,220.47 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $738.66 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $485.78 | 2019-2025 | |
| Romark Laboratories, Lc | $394.01 | 2019-2020 | |
| Pfizer INC. | $311.22 | 2025 | |
| Merck Sharp & Dohme LLC | $223.94 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $202.24 | 2020-2024 | Entyvio |
| Redhill Biopharma INC. | $196.46 | 2020-2022 | |
| Madrigal Pharmaceuticals | $157.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $153.11 | 2021-2025 | Qsymia, Pancreaze |
| Nestle Healthcare Nutrition INC. | $149.87 | 2021-2023 | |
| Medtronic, INC. | $143.90 | 2022 | |
| Exact Sciences Corporation | $132.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $106.68 | 2024-2025 | Zenpep, Vowst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $100.80 | 2019 | |
| Celgene Corporation | $79.63 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $75.31 | 2019-2021 | |
| Qol Medical, LLC | $46.58 | 2025 | Sucraid |
| Novo Nordisk INC | $28.96 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $21.06 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.61 | 2024 | Voquezna |
| Allergan, INC. | $15.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.95 | 2022 | |
| Napo Pharmaceuticals INC | $11.03 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.